Answers are grounded in this paper and cite their sources.
PURPOSE: The aim of this work was to analyze the atazanavir-bilirubin relationship, using a new mathematical approach to pharmacokinetic-pharmacodynamic models, for competitive drug interactions based on Michaelis-Menten equations. PATIENTS AND METHODS: Because atazanavir induces an increase of plasma bilirubin levels, in a concentration-dependent manner, we developed a mathematical model, based on increments of atazanavir and bilirubin concentrations at steady state, in HIV infected (HIV(+)) patients, and plotted the corresponding nomogram for detecting suboptimal atazanavir exposure. RESULTS: By applying the obtained model, the results indicate that an absolute value or an increment of bilirubin at steady state below 3.8 μmol/L, are predictive of suboptimal atazanavir exposure and therapeutic failure. CONCLUSION: We have successfully implemented a new mathematical approach to pharmacokinetic-pharmacodynamic model for atazanavir-bilirubin interaction. As a result, we found that bilirubin plasma levels constitute a good marker of exposure to atazanavir and of viral suppression.
No takes yet. Share an insight, caveat, or question.
Lozano et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: